FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2025/08/093645 [Registered on: 25/08/2025] Trial Registered Prospectively
Last Modified On:
Post Graduate Thesis  No 
Type of Trial  Observational 
Type of Study   Cohort Study 
Study Design  Other 
Public Title of Study   Breast Cancer treatment cost and access to care  
Scientific Title of Study   Catastrophic costs and expenditure and referral pathways influence treatment of Breast cancer in India 
Trial Acronym  Crocodile B 
Secondary IDs if Any  
Secondary ID  Identifier 
version 1.6 Dated10/07/2025  Other 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Deepak Jain  
Designation  Assistant Professor  
Affiliation  Christian Medical College & Hospital Ludhiana 
Address  Department of General Surgery First floor, Room no 1137, Brown Road, Ludhiana

Ludhiana
PUNJAB
141008
India 
Phone  9646212700  
Fax    
Email  drjaindj1985@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Deepak Jain  
Designation  Assistant Professor  
Affiliation  Christian Medical College & Hospital Ludhiana 
Address  Department of General Surgery First floor, Room no 1137, Brown Road, Ludhiana


PUNJAB
141008
India 
Phone  9646212700  
Fax    
Email  drjaindj1985@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Dr Deepak Jain  
Designation  Assistant Professor  
Affiliation  Christian Medical College & Hospital Ludhiana 
Address  Department of General Surgery First floor, Room no 1137, Brown Road, Ludhiana


PUNJAB
141008
India 
Phone  9646212700  
Fax    
Email  drjaindj1985@gmail.com  
 
Source of Monetary or Material Support  
Non funded study. The study is coordinated by the Department of General Surgery and India Hub NIHR Global Health Research Unit on Global Surgery, Christian Medical College & Hospital Ludhiana, Brown Road 141008 Punjab  
 
Primary Sponsor  
Name  Christian Medical College & Hospital Ludhiana  
Address  Christian Medical College & Hospital Ludhiana, Brown Road, 141008, Punjab 
Type of Sponsor  Research institution 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 2  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Deepak Jain  Christian Medical College Hospital Ludhiana   Department of General Surgery, First Floor, room no 1137, Brown Road, Ludhiana 141008
Ludhiana
PUNJAB 
9646212700

drjaindj1985@gmail.com  
Dr Fazlul Qadir Parray   Sher-I- Kashmir Institute of Medical Sciences Srinagar   Department of General Surgery, 1st Floor main building room no 2301 srinagar
Srinagar
JAMMU & KASHMIR 
9419008550

fazlparray@rediffmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 2  
Name of Committee  Approval Status 
Institutional Ethics Committee   Submittted/Under Review 
Institutional Ethics Committee CMC Ludhiana   Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: C509||Malignant neoplasm of breast of unspecified site,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  Nil  Nil 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  99.00 Year(s)
Gender  Female 
Details  1) Adult aged 18 years to 99 Years

2) Consecutive new patients with a histopathology proven breast cancer for whom a CRC treatment plan is made:
o In a multi-disciplinary team meeting (MDT).
o OR in the outpatient clinic where an MDT is not available (surgery, chemotherapy, or radiation therapy outpatient clinic).

3) Undergoing treatment in the hospital where the MDT took place.

4) Participants must be able to provide written informed consent (signature or a fingerprint). 
 
ExclusionCriteria 
Details  1) Patients with no histopathology available.
2) Patients suffering from double primary cancers
3) Patients for whom a treatment plan is made at recurring hospitals who undergo the full course of treatment in another hospital will be excluded.
4) Patient on Palliative therapy
5) Telephone follow-up not possible.  
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Not Applicable 
Blinding/Masking   Not Applicable 
Primary Outcome  
Outcome  TimePoints 
The primary outcome of this study will be catastrophic expenditure at 3 months, 6
months and 1 year after the treatment decision. 
The primary outcome of this study will be catastrophic expenditure at 3 months, 6
months and 1 year after the treatment decision. 
 
Secondary Outcome  
Outcome  TimePoints 
1. Treatment compliance rate at 3 months, 6 months and at 1 year after treatment
decision.
2. The five most expensive items comprising breast cancer treatment costs. 
At 3 months, 6 months and at 1 year after treatment  
 
Target Sample Size   Total Sample Size="1030"
Sample Size from India="1030" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   N/A 
Date of First Enrollment (India)   25/08/2025 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="6"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

Catastrophic costs and expenditure and referral pathways influence treatment of Breast cancer in India: (CROCODILE-B)

The aim of the study is to identify financial and non-financial barriers to comply with treatment for breast cancer in India. The study will be a mixed-methods study comprising quantitative data from up to 10 tertiary hospitals and qualitative work from interviews with patients and healthcare professionals where the outcome is the incidence of catastrophic expenditure due to out-of-pocket payments for cancer care at 3 months and 6 months and 1 year after breast cancer diagnosis. A mixed method study is being done as we are looking at identifying barriers to adherence to therapy as well as the patient’s ability to cope with the costs of treatment.

Study Setting and design: This study will be run in ten hospitals in India where cancer treatment is available and routinely delivered. This will be a prospective, multicentric, mixed-methods study with two main workstream: 1. Quantitative workstream: a prospective cohort study to determine the catastrophic expenditure 2. Qualitative workstream: to explore patient and professionals perspectives about the barriers to breast cancer treatment compliance.

The primary objective of this study is to identify the proportion of breast cancer patients suffering catastrophic expenditure due to out-of-pocket payments for cancer treatments. The secondary objectives are: 1. To assess the catastrophic expenditure rate at 3 months, 6 months and 1 year after diagnosis. 2. To identify the main drivers of treatment costs in breast cancer treatment.

Sample size: 1030 patients

Duration: 01 year 6 months

Statistical Analysis

All analyses will be conducted using the intention to treat (ITT) principle, which means that patients’ outcomes will be examined in relation to their initial treatment plan (surgery, chemotherapy, radiotherapy). Summary statistics will be supplied for all outcome measures using counts and percentages for categorical variables and means and standard deviations and/or medians and interquartile ranges for continuous variables. To test for differences across comparisons of categorical variables, the Chi square test will be utilized. Welch’s t-test or ANOVA will be used for continuous data that is parametric in character (as visually appraised). The Wilcoxon rank sum or Kruskall-Wallis tests will be employed for non-parametric data. All the analysis will be undertaken using the R studio software (v2023.12.0+369).

 
Close